Outcome of Board Meeting to considered and approve Audited Financials for the year ended March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Kapil Cotex Limited approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. Auditor SPD & Associates issued an unmodified (clean) opinion on both sets of results. On a standalone basis, revenue from operations collapsed to just Rs. 0.16 lakh (from Rs. 60.36 lakh last year), though the company reported a profit of Rs. 48.66 lakh aided by Rs. 187.50 lakh in exceptional items and other income of around Rs. 200 lakh. On a consolidated basis, after incorporating the newly acquired 72.51% subsidiary Skybiotech Life Sciences Pvt Ltd (acquired in Q2 FY25), the group swung to a loss of Rs. 236.97 lakh versus a prior-year profit of Rs. 153.53 lakh. The subsidiary alone contributed a net loss of Rs. 242.86 lakh on income of Rs. 725.32 lakh. Consolidated operating cash flow turned negative at Rs. -104.25 lakh.
Shareholders should note a sharp deterioration in consolidated profitability, driven mainly by losses at the recently acquired subsidiary, while the core standalone business remains minimal. The negative consolidated EPS of Rs. -14.19 (vs Rs. 3.67) and negative operating cash flow could weigh on investor sentiment and the stock price in the near term.